M L Salgaller

Summary

Publications

  1. ncbi request reprint Immune monitoring of cancer patients undergoing experimental immunotherapy
    G Shankar
    Antigen Research and Discovery, Northwest Biotherapeutics Inc, Suite 200, 2203 Airport Way South Seattle, WA 98134, USA
    Curr Opin Mol Ther 2:66-73. 2000
  2. ncbi request reprint The development of immunotherapies for non-small cell lung cancer
    Michael L Salgaller
    Northwest Biotherapeutics, Inc, Suite 100, 21720 23rd Drive SE, Bothell, WA 98021, USA
    Expert Opin Biol Ther 2:265-78. 2002
  3. ncbi request reprint Prostate cancer immunotherapy at the dawn of the new millennium
    M L Salgaller
    Northwest Biotherapeutics, Inc, 2203 Airport Way South, Suite 200, Seattle, WA 98134, USA
    Expert Opin Investig Drugs 9:1217-29. 2000
  4. ncbi request reprint American Association for Cancer Research: Clinical trials of immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco, CA, USA
    M L Salgaller
    Antigen Research and Development Division, Northwest Biotherapeutics, Inc, Seattle, WA 98134, USA
    Expert Opin Investig Drugs 9:1413-7. 2000
  5. ncbi request reprint Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
    M L Salgaller
    Northwest Biotherapeutics, L L C, Pacific Northwest Cancer Foundation, Seattle, Washington 98125, USA
    Prostate 35:144-51. 1998
  6. ncbi request reprint Use of cellular and cytokine adjuvants in the immunotherapy of cancer
    M L Salgaller
    Pacific Northwest Cancer Foundation and Immunotherapeutics Division, Northwest Biotherapeutics, L L C, Seattle, Washington 98125, USA
    J Surg Oncol 68:122-38. 1998
  7. ncbi request reprint American Association for Cancer Research: dendritic cells: strategies and vaccines. April 1-5, 2000, San Francisco, CA, USA
    M L Salgaller
    Division of Antigen Research and Development, Nortwest Biotherapeutics, Inc, Seattle, WA, USA
    Expert Opin Investig Drugs 9:1407-12. 2000
  8. ncbi request reprint Progress in active-specific immunotherapy of brain malignancies
    B A Tjoa
    Northwest Biotherapeutics, Inc, 21710 23rd Drive SE, Suite 100, Bothell, WA 98021, USA
    Expert Opin Investig Drugs 9:2093-101. 2000
  9. ncbi request reprint Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line
    Yaling Zhou
    Department of Molecular Medicine, Northwest Hospital, Suite 101, Bothell, Washington 98021, USA
    Biochem Biophys Res Commun 290:830-8. 2002
  10. ncbi request reprint Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity
    Yaling Zhou
    Northwest Biotherapeutics, Incorporated, Bothell, Washington 98021, USA
    J Immunother 25:289-303. 2002

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Immune monitoring of cancer patients undergoing experimental immunotherapy
    G Shankar
    Antigen Research and Discovery, Northwest Biotherapeutics Inc, Suite 200, 2203 Airport Way South Seattle, WA 98134, USA
    Curr Opin Mol Ther 2:66-73. 2000
    ..The purpose of this article is to review the methods currently utilized to evaluate the induction, maintenance, and duration of antitumor immune reactivity in cancer patients undergoing immunotherapy...
  2. ncbi request reprint The development of immunotherapies for non-small cell lung cancer
    Michael L Salgaller
    Northwest Biotherapeutics, Inc, Suite 100, 21720 23rd Drive SE, Bothell, WA 98021, USA
    Expert Opin Biol Ther 2:265-78. 2002
    ..In general, there are many tactics under development for the treatment of NSCLC. This review primarily concerns immunotherapeutic cancer treatments that are either already in clinical trial or well progressed into preclinical studies...
  3. ncbi request reprint Prostate cancer immunotherapy at the dawn of the new millennium
    M L Salgaller
    Northwest Biotherapeutics, Inc, 2203 Airport Way South, Suite 200, Seattle, WA 98134, USA
    Expert Opin Investig Drugs 9:1217-29. 2000
    ..The following review concentrates on those approaches that are currently in human or animal studies and have a specific emphasis on prostate cancer...
  4. ncbi request reprint American Association for Cancer Research: Clinical trials of immunotherapeutics and immunologic monitoring. April 1-5, 2000, San Francisco, CA, USA
    M L Salgaller
    Antigen Research and Development Division, Northwest Biotherapeutics, Inc, Seattle, WA 98134, USA
    Expert Opin Investig Drugs 9:1413-7. 2000
    ..Others discussed ways in which those in the immunotherapy community can work towards more reliable immune monitoring and ultimately a surrogate marker for response...
  5. ncbi request reprint Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA)
    M L Salgaller
    Northwest Biotherapeutics, L L C, Pacific Northwest Cancer Foundation, Seattle, Washington 98125, USA
    Prostate 35:144-51. 1998
    ..In this paper we describe our program for the immune monitoring of phase II participants given dendritic cell (DC)/prostate-specific membrane antigen (PSMA)-based immunotherapy, and we also present some initial findings...
  6. ncbi request reprint Use of cellular and cytokine adjuvants in the immunotherapy of cancer
    M L Salgaller
    Pacific Northwest Cancer Foundation and Immunotherapeutics Division, Northwest Biotherapeutics, L L C, Seattle, Washington 98125, USA
    J Surg Oncol 68:122-38. 1998
    ..With each report reaching the literature, more effective clinical trials are being designed and implemented...
  7. ncbi request reprint American Association for Cancer Research: dendritic cells: strategies and vaccines. April 1-5, 2000, San Francisco, CA, USA
    M L Salgaller
    Division of Antigen Research and Development, Nortwest Biotherapeutics, Inc, Seattle, WA, USA
    Expert Opin Investig Drugs 9:1407-12. 2000
    ..Many studies have advanced from in vitro work and demonstrated utility in various animal models. Ultimately, there is the hopeful, steady progress into the increasing numbers of experimental immunotherapies against human cancer...
  8. ncbi request reprint Progress in active-specific immunotherapy of brain malignancies
    B A Tjoa
    Northwest Biotherapeutics, Inc, 21710 23rd Drive SE, Suite 100, Bothell, WA 98021, USA
    Expert Opin Investig Drugs 9:2093-101. 2000
    ..Preclinical work on the use of dendritic cell-based vaccine for malignant brain tumours are encouraging. The move from these preliminary studies to the clinic is anticipated with high hope...
  9. ncbi request reprint Serological cloning of PARIS-1: a new TBC domain-containing, immunogenic tumor antigen from a prostate cancer cell line
    Yaling Zhou
    Department of Molecular Medicine, Northwest Hospital, Suite 101, Bothell, Washington 98021, USA
    Biochem Biophys Res Commun 290:830-8. 2002
    ..Thus, the PARIS-1 protein may play a role in regulation of cell differentiation and growth or represent a new member of the Rab-GAP family...
  10. ncbi request reprint Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity
    Yaling Zhou
    Northwest Biotherapeutics, Incorporated, Bothell, Washington 98021, USA
    J Immunother 25:289-303. 2002
    ..This review provides a brief summary on these methods, the techniques used in these methods, as well as the advantages and disadvantages of each method...
  11. ncbi request reprint Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses
    Yaling Zhou
    Vaccine Research and Development Division, Northwest Biotherapeutics Inc, 21720 23rd Drive SE, Suite 100, Bothell, WA 98021, USA
    Cancer Immunol Immunother 52:413-22. 2003
    ..Our results demonstrate the feasibility of using lung tumor cell-loaded DC to induce immune responses against lung cancer-associated antigens and support ongoing efforts to develop a DC-based lung cancer vaccine...
  12. ncbi request reprint A manifesto on the current state of dendritic cells in adoptive immunotherapy
    Michael L Salgaller
    Transfusion 43:422-4. 2003
  13. ncbi request reprint Current status of clinical trials for glioblastoma
    Michael L Salgaller
    Toucan Capital Corp, Bethesda, MD 20814, USA
    Rev Recent Clin Trials 1:265-81. 2006
    ..This article summarizes the preclinical proof-of-concept research and human studies involving some of the agents creating the most positive buzz in the medical community. The advantages and limitations of each are described...